Project Grant R33CA297969
Award Date
5/1/25
Completion Date
4/30/28
Dollars Obligated
$392K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $444,569 over a 2-year period from June 1, 2024 to May 31, 2026 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to develop more representative patient-derived models of hormone receptor positive (HR+) breast cancer, including those from underrepresented ethnicities. The award aims to expand the availability of these models and investigate therapeutic...
The National Cancer Institute (NCI) awarded a $1,343,188 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at understanding the development of drug resistance in cancer. The 5-year project, which commenced on June 15, 2024, will utilize a mouse model of squamous cell carcinoma to investigate the molecular mechanisms underlying the emergence of highly heterogeneous, drug-resistant...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $695,916 to The Regents of the University of California, San Francisco (UCSF) to evaluate and optimize novel sphingomyelinase 2 (nSMase2) inhibitors for enhancing the efficacy of immune checkpoint inhibitors in cancer treatment. The goal is to identify 1-2 optimized nSMase2 inhibitor prodrugs with good oral bioavailability, acceptable safety, and robust efficacy in inhibiting tumor...
The National Cancer Institute (NCI) awarded a $3,537,456 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Regents of the University of California, San Francisco (UCSF) to support a comprehensive research program to advance the science and evaluation of subtype-specific risk-based breast cancer screening and prevention. The key products and services delivered through this award include: Extending enrollment of the WISDOM study to 45,000 women in the U.S....
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,472,329 to the University of California, Irvine to characterize and utilize a recently-developed in vitro microphysiological system (MPS) model of peritoneal carcinomatosis (PC). The goal is to use this vascularized micro-peritoneum (VMP) model as a therapeutic development tool to identify improved treatments for PC, which is the deadliest form of colorectal and gastric...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $585,931 to the University of Pittsburgh to conduct research aimed at evaluating and selecting the most representative cancer models, such as cell lines and patient-derived organoids, for use in precision cancer research and clinical applications. The key objectives are to: 1) identify and clinically annotate prevalent tumor subclones and microenvironment cell types in...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is for a project titled "Engineered Biomimetic Collective Cancer Invasion Models for Screening Chemotherapeutic Agents." The $443,191 award, with a project period running from June 2024 to May 2029, aims to develop innovative in vitro tumor invasion models using engineered biomimetic substrates and 3D tissue-engineered constructs. These models will...
This $654,197 federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) supports research at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop and utilize patient-derived xenograft (PDX) tumor models to study molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) and their response to standard-of-care and investigational therapies. The key objectives are to: 1) Define the molecular...
The Regents of the University of California, San Francisco (UCSF) has been awarded a $1,453,500 Project Grant under the Trans-NIH Research Support (CFDA 93.310) program, administered by the National Institutes of Health (NIH). The grant, titled "Simulating Ancestrally Unbiased Tumor Evolution to Interrogate Drug Resistance Among Cancer Patients of Distinct Ancestries," aims to develop an immunocompetent organoid-based tumor graft system, called BRUTE (Barcoded Unsupervised Tumor...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $667,118 in funding to The Regents of the University of California, San Francisco to conduct research aimed at identifying and disabling new pathways for macromolecular recycling in pancreatic cancer. The key products and services being delivered through this 5-year project include: Exploring the role of the lysosomal hydrolase PLBD1 in enabling pancreatic cancer cell metabolism by...